LabCorp's Drug Development Business, Covance, Acquires GlobalCare


LabCorp recently announced the company’s drug development business, Covance, has acquired GlobalCare, a globally recognized industry leader in patient-centric decentralized clinical trials support services.

This acquisition will expand Covance’s decentralized clinical trials capabilities globally, enabling recruitment and increasing access to trials. Specifically, Covance will leverage GlobalCare’s mobile healthcare services, site staffing support, patient transport assistance and contracted central pharmacy services, complementing and strengthening Covance’s decentralized trial capabilities.

This acquisition will benefit GlobalCare’s current and future customers by providing access to needed resources and technology to scale services to meet growing industry needs. GlobalCare will also complement its existing services with additional important decentralized clinical trial services via Covance capabilities such as eConsent, tele-health, Electronic Data Capture (EDC), online patient scheduling, connected device solutions, and more. This transaction allows for seamless integration of a full suite of biopharmaceutical services.

In November 2019, Covance launched its cohesive Decentralized Clinical Trials (DCT) solutions, which integrate unique capabilities from across the company’s leading diagnostic and drug development business units, redefining the patient experience to increase participation.

For more information about Covance and its DCT capabilities, click here.

For more information about GlobalCare, click here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.